Eton Pharmaceuticals Updates Hemangeol Prescribing Information for Infantile Hemangioma
Key Insights
Eton Pharmaceuticals (search) updated the prescribing information for Hemangeol (propranolol hydrochloride) oral solution on September 14, 2026.
The revised label covers clinical data and safety guidance for proliferating infantile hemangioma (search) requiring systemic therapy.
It details weight-based dosage adjustments, side-effect monitoring, contraindications, and cardiovascular and respiratory warnings.
Eton Pharmaceuticals (search) updated the prescribing information for Hemangeol (propranolol hydrochloride) oral solution on September 14, 2026. The drug is indicated for the treatment of proliferating infantile hemangioma (search) requiring systemic therapy.
The updated filing outlines specific administration protocols, including dosage adjustments based on the patient's weight and the necessity of monitoring for potential side effects. It also details the drug's pharmacological properties, contraindications, and warnings regarding cardiovascular and respiratory risks associated with treatment.
Healthcare providers can access the full prescribing information through the National Library of Medicine's DailyMed database, which includes the complete clinical data, drug interaction information, and adverse reactions observed during clinical trials.